title: High susceptibility to severe infectious complications at reinduction chemotherapy in patients who relapse after stem cell transplantation.
abstract: Patients who relapse after stem cell transplantation (SCT) usually appear to be liable to severe infectious complications at reinduction chemotherapy compared to patients at the first induction therapy, though this is not statistically substantiated. The aim of this study was to analyze episodes of infectious complications during reinduction chemotherapy among patients who relapsed after SCT compared with those at the first induction chemotherapy. Between February 1988 and March 2004, 145 children received SCT, and 17 (12 with hematologic malignancies and 5 with solid tumors) were enrolled as eligible subjects for this study. Positive blood cultures (sepsis) were present in six patients exclusively at the reinduction therapy but none at the first induction (P = .009). Three of the six patients progressed to septic shock. Moreover, all patients positive for blood cultures were those with hematologic malignancy (P = .007), and every patient with septic shock had received allogenic transplantation. Our results showed that reinduction chemotherapy needs attention for severe infectious complications, particularly among patients with hematologic malignancies receiving allogenic transplantations. Possible immaturity of the reconstructed systemic immune system and/or insufficient recovery of mucosal protective functions in the patients after SCT are discussed in view of their high susceptibility to severe infectious complications.
authors.affiliation: Department of Pediatrics, Hokkaido University Graduate School of Medicine, Hokkaido, Japan. shoyu5p@asahikawa-med.ac.jp
authors.forename: A
authors.initials: A
authors.lastname: Iguchi
authors.forename: R
authors.initials: R
authors.lastname: Kobayashi
authors.forename: T Z
authors.initials: TZ
authors.lastname: Sato
authors.forename: H
authors.initials: H
authors.lastname: Naito
authors.forename: T
authors.initials: T
authors.lastname: Shikano
authors.forename: Y
authors.initials: Y
authors.lastname: Ishikawa
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000453:epidemiology; D002648:Child; D002675:Child, Preschool; D004198:Disease Susceptibility; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D007223:Infant; D007239:Infections / Q000453:epidemiology*; D008297:Male; D009369:Neoplasms / Q000601:surgery*; D009503:Neutropenia / Q000139:chemically induced / Q000453:epidemiology; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D019172:Transplantation Conditioning / Q000379:methods
chemical_list: D000970:Antineoplastic Agents